Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Existe información en español para pacientes y cuidadores, para acceder, haga clic sobre “Select” al lado de “I am a U.S. Patient / Caregiver”.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

atracurium besylate injection, USP How Supplied/Storage and Handling

HOW SUPPLIED

Atracurium Besylate Injection USP, each mL containing 10 mg atracurium besylate, is supplied as follows:

Unit of SaleConcentration
*
Contains benzyl alcohol (see WARNINGS).
NDC 0409-1109-01
Carton of 10 Single dose Vials
50 mg/5 mL
(10 mg/mL)
NDC 0409-1105-02
*Carton of 10 Multiple dose Vials
100 mg/10 mL
(10 mg/mL)

Atracurium Besylate Injection should be refrigerated at 2°C to 8°C (36°F to 46°F) to preserve potency. DO NOT FREEZE. Protect from light. Keep vials in carton until time of use.

Upon removal from refrigeration to room temperature storage conditions (25°C/77°F), use Atracurium Besylate Injection within 14 days even if rerefrigerated.

 

Manufactured by:

Gland Pharma Limited;

Hyderabad 500043, India

 

Logo

Manufactured for:

Hospira, Inc.

Lake Forest, IL 60045 USA

 

 

LAB-1214-4.0
Revised: 07/2021

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event